First, it provides one more strong evidence that CD4+ T cells are not just the supporting roles in antitumor immunity compared to CD8+ T cells, and even outperform CD8+ T cells under certain circumstances.5 Second, it offers direct evidence that type 2 immune response suppresses tumor development in an unexpected manner, underlining its prominent role in restraining angiogenesis and tumor progression in subsets of cancer patients.1 Lastly, it provides a new strategy for targeting TGF-β signaling in the TME. The gene discussed is CD8A; the disease is cancer.